At the news
? NEUTRALIMPACT 3/10 DEFA14A filed Apr 23, 2026 at 16:10 ET
BioCryst Pharmaceuticals is holding its 2026 annual meeting to vote on several proposals, including the election of three directors, ratification of auditors, an advisory vote on executive compensation, and approval of an amended stock incentive plan to increase shares available for issuance. This is a routine annual shareholder meeting with no activist involvement or contested issues.
- Annual meeting scheduled for June 11, 2026
- Three director nominees: Theresa M. Heggie, Amy E. McKee, M.D., and Jon P. Stonehouse
- Proposal to ratify Ernst & Young LLP as independent auditors
- Advisory vote on executive compensation
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access